Compare CLNN & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLNN | NSPR |
|---|---|---|
| Founded | 2012 | 2005 |
| Country | United States | United States |
| Employees | 79 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.7M | 72.1M |
| IPO Year | N/A | 2009 |
| Metric | CLNN | NSPR |
|---|---|---|
| Price | $6.07 | $1.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $33.75 | $4.00 |
| AVG Volume (30 Days) | ★ 671.8K | 290.7K |
| Earning Date | 05-08-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,310,000.00 |
| Revenue This Year | $17.64 | $57.98 |
| Revenue Next Year | $19,516.77 | $95.41 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.25 | $0.86 |
| 52 Week High | $13.50 | $2.93 |
| Indicator | CLNN | NSPR |
|---|---|---|
| Relative Strength Index (RSI) | 44.04 | 40.41 |
| Support Level | $5.56 | N/A |
| Resistance Level | $6.92 | $1.29 |
| Average True Range (ATR) | 0.53 | 0.07 |
| MACD | -0.10 | 0.00 |
| Stochastic Oscillator | 14.69 | 35.20 |
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.